Metformin in Alzheimer's Dementia Prevention (MAP)

Clinical Trial Title

The purpose of this study is to test whether the drug Glucophage® XR (generic name metformin extended-release tablets) can prevent cognitive decline among persons with mild cognitive impairment.

National Clinical Trial Number:


Contact Information

Clinical Trial Protocol Description:

The purpose of this study is to test the efficacy of the drug Glucophage® XR Metformin (generic name metformin extended-release tablets) in the prevention of cognitive decline associated with Alzheimer’s dementia. Nationwide, 370 participants will be recruited for this study at 11 sites across the United States. At Rush University Medical Center, we expect to recruit up to 30 participants.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Be 55-90 years old.
  • Have a diagnosis of MCI or a subjective memory complaint.
  • You have not been diagnosed with diabetes or dementia.
  • Have an individual who knows you well willing to take part in the study with you as your study partner.

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Zoe Arvanitakis, PhD

Contact Information

Michael Pessman

Clinical Trial Location

RUSH University Medical Center


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more